Macro Finance
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal
Bloomberg Markets·September 28, 2026·1 min read
Summit Therapeutics Inc. shares jumped after AstraZeneca Plc announced a $2 billion strategic equity investment in the cancer drugmaker. The two companies will jointly develop drugs, a deal that provides Summit with significant capital and validates its pipeline, boosting investor confidence.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.